128 related articles for article (PubMed ID: 38018049)
1. [Efficacy and safety of intermediate-dose cytarabine in the treatment of children with refractory high risk Langerhans cell histiocytosis].
Wang WQ; Ge J; Ma HH; Lian HY; Cui L; Zhang L; Li ZG; Wang TY; Zhang R
Zhonghua Er Ke Za Zhi; 2023 Dec; 61(12):1118-1123. PubMed ID: 38018049
[No Abstract] [Full Text] [Related]
2. Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone.
Wang W; Ge J; Ma H; Lian H; Cui L; Zhao Y; Li Z; Wang T; Zhang R
BMC Pediatr; 2024 Jan; 24(1):1. PubMed ID: 38172736
[TBL] [Abstract][Full Text] [Related]
3. [Recurrent and Refractory Langerhans Cell Histiocytosis in Children Treated with the Combination of Cladribine and Cytarabine].
DU Y; Xiong H; Li H; Li JX; Tao F; Yang L; Lu WJ; Qi SS; Zhang LN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):943-949. PubMed ID: 35680831
[TBL] [Abstract][Full Text] [Related]
4. Second-line regimen for CNS-involved pediatric Langerhans cell histiocytosis.
Lian H; Cui L; Yang Y; Wei A; Cheng H; Li N; Zhang L; Ma H; Zhao X; Wang T; Li Z; Zhang R
Pituitary; 2022 Feb; 25(1):108-115. PubMed ID: 34302575
[TBL] [Abstract][Full Text] [Related]
5. Cladribine and cytarabine in children refractory high risk multisystem Langerhans cell histiocytosis.
Wang W; Ge J; Ma H; Lian H; Cui L; Zhao Y; Li Z; Wang T; Zhang R
Heliyon; 2023 Sep; 9(9):e19277. PubMed ID: 37681174
[TBL] [Abstract][Full Text] [Related]
6. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.
Donadieu J; Bernard F; van Noesel M; Barkaoui M; Bardet O; Mura R; Arico M; Piguet C; Gandemer V; Armari Alla C; Clausen N; Jeziorski E; Lambilliote A; Weitzman S; Henter JI; Van Den Bos C;
Blood; 2015 Sep; 126(12):1415-23. PubMed ID: 26194764
[TBL] [Abstract][Full Text] [Related]
7. [Cladribine for 13 cases refractory high-risk children Langerhans cell histiocytosis].
Hu T; Liu R; Li J; Cao J; Zhang L; Li J; Fan W; Zhong D; Shi X
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):985-9. PubMed ID: 25417874
[TBL] [Abstract][Full Text] [Related]
8. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside.
Apollonsky N; Lipton JM
J Pediatr Hematol Oncol; 2009 Jan; 31(1):53-6. PubMed ID: 19125089
[TBL] [Abstract][Full Text] [Related]
9. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
[TBL] [Abstract][Full Text] [Related]
10. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
11. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction.
Bernard F; Thomas C; Bertrand Y; Munzer M; Landman Parker J; Ouache M; Colin VM; Perel Y; Chastagner P; Vermylen C; Donadieu J
Eur J Cancer; 2005 Nov; 41(17):2682-9. PubMed ID: 16291085
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review.
Néel A; Artifoni M; Fontenoy AM; Tessoulin B; Lorillon G; Cohen-Aubart F; Haroche J; Genereau T; de Menthon M; Guillevin L; Maillard H; Kahn JE; Hermine O; Araujo C; Dromer C; Jullien D; Hamidou M; Donadieu J; Tazi A
Br J Haematol; 2020 Jun; 189(5):869-878. PubMed ID: 32191819
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A; Robak T; Lech-Marańda E; Wierzbowska A; Dmoszyńska A; Kowal M; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Maj S; Hellmann A; Skotnicki A; Jedrzejczak W; Kuliczkowski K;
Eur J Haematol; 2003 Sep; 71(3):155-62. PubMed ID: 12930315
[TBL] [Abstract][Full Text] [Related]
14. Reduced doses of cladribine and cytarabine regimen was effective and well tolerated in patients with refractory-risk multisystem Langerhans cell histiocytosis.
Rosso DA; Amaral D; Latella A; Chantada G; Braier JL
Br J Haematol; 2016 Jan; 172(2):287-90. PubMed ID: 25944303
[No Abstract] [Full Text] [Related]
15. [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation].
Adam Z; Rehák Z; Koukalová R; Szturz P; Krejčí M; Pour L; Zahradová L; Moulis M; Kodet R; Nebeský T; Brejcha M; Adamová Z; Hájek R; Mayer J
Vnitr Lek; 2012 Jan; 58(1):62-71. PubMed ID: 22448704
[TBL] [Abstract][Full Text] [Related]
16. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: a single institutional experience.
Biswas G; Khadwal A; Arora B; Bhagwat R; Banavali SD; Nair CN; Pai SK; Kurkure PA; Parikh PM
Indian J Cancer; 2007; 44(4):137-41. PubMed ID: 18322355
[TBL] [Abstract][Full Text] [Related]
17. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
[TBL] [Abstract][Full Text] [Related]
19. Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison.
Shen Y; Chen J; Liu Y; Wu D
Chemotherapy; 2014; 60(5-6):368-74. PubMed ID: 26496511
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal involvement in disseminated Langerhans cell histiocytosis (LCH) with durable complete response to 2-chlorodeoxyadenosine and high-dose cytarabine.
Choi SW; Bangaru BS; Wu CD; Finlay JL
J Pediatr Hematol Oncol; 2003 Jun; 25(6):503-6. PubMed ID: 12794533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
